AI Article Synopsis
- DMF can cause grade 3 lymphopenia in patients with RRMS, with an observed frequency of 4.5% in a study involving 246 patients.
- Lymphocyte counts in patients generally returned to normal levels (≥800/µl) within six months after stopping DMF treatment.
- Older age was identified as a factor associated with a longer recovery time for lymphocyte levels post-DMF withdrawal, highlighting the need for further research into this issue.
Article Abstract
Background: Dimethyl fumarate (DMF) is licensed for treatment of relapsing-remitting multiple sclerosis (RRMS). DMF can induce lymphopenia, which is assumed to increase the risk for opportunistic infections like progressive multifocal leukoencephalopathy. Our goal for this work was to estimate the frequency of grade 3 lymphopenia in DMF-treated patients with RRMS and to characterize patient-sided factors influencing the time course of lymphocyte repopulation after DMF withdrawal.
Material And Methods: A single-center retrospective data analysis was performed at University Hospital Bern, Switzerland. Patients with DMF treatment were analyzed for lymphocyte counts. Demographic factors were statistically analyzed in grade 3 lymphopenic patients.
Results: We estimated a grade 3 lymphopenia frequency of 11/246 (4.5%), corroborating previous studies. In all patients, lymphocytes recovered to values ⩾800/µl within 0.5 years. Multivariate linear regression analysis unmasked older age as being associated with a longer duration of repopulation.
Conclusion: Considering the aging population, our findings warrant further investigations of DMF-induced lymphopenia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506915 | PMC |
| http://dx.doi.org/10.1177/1756286419843450 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!